Exclusive: Shareholder revolt threatens Alcon's takeover of STAAR Surgical

STAAR Surgical Company has agreed to a $28 per share acquisition by Alcon Inc., a valuation significantly below earlier proposals, drawing strong opposition from its largest shareholder, Broadwood Partners. Broadwood, holding 27.3%, alleges an inadequate sale process, citing a lack of market check, a rushed timeline preventing competing bids, and Alcon's opportunistic timing to acquire STAAR at a depressed valuation following recent China sales volatility and ahead of anticipated favorable clinical trial results for STAAR's proprietary EVO ICL technology. The hedge fund asserts STAAR, a dominant player in the phakic IOL market with robust patent protection, is fundamentally undervalued, and is urging other shareholders to reject the deal, potentially paving the way for a rival bid during the remaining "window-shop" period.

Analysis

The proposed acquisition of STAAR Surgical (STAA) by Alcon (ALC) for $28 per share is facing significant shareholder opposition, creating substantial uncertainty around the deal's closure at its current terms. The offer represents a sharp discount from a previously discussed $58 per share valuation, a decline that follows a severe 99% Q1 2025 revenue collapse in China due to distributor inventory destocking and macroeconomic weakness. STAAR's largest shareholder, Broadwood Partners, with a 27.3% stake, is actively campaigning against the merger, alleging an inadequate sale process orchestrated by the board. Key criticisms include the absence of a formal market check by advisor Citigroup, a compressed one-day timeline given to two other interested parties, and opportunistic timing by Alcon to acquire STAAR just as it shows signs of resolving its operational challenges and ahead of potentially value-accretive clinical trial results. Despite its recent stock price decline, STAAR maintains a dominant market position, controlling over 90% of the phakic IOL market by revenue, underpinned by a strong patent moat on its proprietary technology extending into the 2030s. The controversy is amplified by governance concerns, including a board chair with prior consulting ties to Alcon and a historical pattern of aggressive acquisition tactics by Alcon, as alleged in the separate Aurion Biotech litigation, framing this as a potential strategic move to neutralize a key competitor at a moment of weakness.

Key Decisions for Investors

• Investors in STAAR should recognize the significant probability of the current deal being blocked or renegotiated, given the 27.3% opposition from Broadwood Partners; the emergence of a superior offer is a distinct possibility, making a hold or speculative buy strategy viable.
• Event-driven funds may find an opportunity in the valuation gap between the $28 offer price and STAAR's potential standalone value, but must weigh the risk of the deal collapsing without a superior bid against the potential for a bidding war emerging before or after the September 19 'window-shop' period expires.
• Alcon shareholders should monitor for a potential increase in the acquisition price, as a higher bid to appease STAAR's dissident shareholders could erode the 'bargain' value of the initial deal, alongside potential litigation and reputational risks associated with the aggressive M&A strategy.
• All parties should closely watch for the imminent clinical trial results comparing EVO ICL to LASIK, as data favoring STAAR would materially strengthen its negotiating position and standalone valuation, serving as a primary catalyst for the stock irrespective of the current deal's outcome.